Seliciclib: Interim Phase I data

Interim data from 11 evaluable patients with advanced solid tumors in an open-label, U.S. Phase I trial showed that sequential administration of oral sapacitabine and oral seliciclib led to 2 partial responses (1 patient with pancreatic cancer and 1 patient with breast cancer), plus 1 case of stable disease (1 patient with ovarian cancer). All 3 responders were reported to be carriers of breast cancer early onset (BRCA) mutations, which Cyclacel said could be a potential biomarker for identifying responders to the combination across multiple solid tumor types. The trial has enrolled 27 patients. ...